Company news

C4 Therapeutics, Inc. news in 2025

C4 Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

November 25, 2025

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 6, 2025

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

October 16, 2025

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

October 1, 2025

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

September 4, 2025

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

September 3, 2025

Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors

August 12, 2025

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 7, 2025

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 27, 2025

C4 Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2025

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

January 13, 2025

C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Decks in 2025